NEW YORK and HOLLISTON, Mass., Feb. 3, 2016 /PRNewswire/ -- Harvard Apparatus Regenerative Technology, Inc. (Nasdaq: HART), a biotechnology company developing bioengineered organ implants for life-threatening conditions of the esophagus, trachea and bronchus, today announced that CEO Jim McGorry, will present at the BIO CEO & Investor Conference on Tuesday, February 9, 2016 at 8:00 am EST in New York City. HART's presentation will be webcast live and available for replay.
Live Webcast/Replay: http://investor.harvardapparatusregen.com/events-calendar
About HART: (www.hartregen.com)
Harvard Apparatus Regenerative Technology (HART) makes bioengineered implants for life-threatening conditions. Our technology platform is to be used to restore function in the esophagus and the trachea and bronchus airways. Our first generation tracheal implant has been used successfully in five adult human implant procedures approved under compassionate use exemptions, but none of our products are yet approved for marketing by a government regulatory authority. HART is completing further large-animal studies to refine our technology platform with the goals of pursuing one or more compassionate use implantation surgeries and filing an Investigational New Drug (IND) application with the U.S. Food and Drug Administration in 2016, seeking to initiate clinical trials for one of our three product candidates.
About BIO CEO Investor Conference: (BIO CEO & Investor Conference) The BIO CEO & Investor Conference is one of the largest investor conferences focused on established and emerging publicly traded and select private biotech companies.
Investor Relations: Catalyst Global LLC David Collins, Tanya Kamatu 212-924-9800 firstname.lastname@example.org
SOURCE Harvard Apparatus Regenerative Technology, Inc.